Refereed Publications

CURTIS, G.C. and BARNES, L. (2008): Inhaled Drugs: Fate and effects in machine-perfused ex vivo human lungs. Ex Vivo Metrics™. CRO publication; Bowman Reserch Inc., Chicago, USA.[P31]

MARUYAMA Y, CHAMBERS DJ. (2008): Myocardial protection: Efficacy of a novel magnesium-cardioplegia (RS-C) compared to St Thomas’ Hospital cardioplegic solution. Interact CardioVasc Thorac Surg 7: 745-749.[P28]

MARK D. KAY, SARAH A. HOSGOOD, SIMON J. F. HARPER, HELEN L. WALLER, DOUGLAS REES AND MICHAEL L. NICHOLSON (2008): Normothermic versus Hypothermic Ex vivo flush using a novel phosphate-free preservation solution in porcine kidneys. Transplantation (submitted)

YUJI MARUYAMA and DAVID J. CHAMBERS (2008): Myocardial protection: Efficacy of RS-C (AQIX®), a novel cardioplegic solution, compared to St Thomas’ Hospital solution. J Mol Cell Cardiol., 44; 711-825: abst. No. 117.[P26]

AMMED YASIN MB BCh., MICHELLE C. MCDONALD PhD., AHILA SIVARAJAH PhD., JULIUS E. KIESWICH BSc., MOHAMMED M. YAQOOB MD FRCP., CHARLES J. HINDS FRCA., CHRISTOPH THIEMERMANN, MD PhD FMedSci. (2007): Clonidine Augments Cardiomyocyte Apoptosis Caused by In Vivo Ischaemia and Reperfusion.[P25]

TOSHINAGA OZEKI, PhD; MICHAEL H. KWON, BS; JUNYAN G.U, PhD; MICHAEL J. COLLINS, BS; JOHN M. BRASSIL, BS; MICHAEL B. MILLER JR, BS; RAO P. GULLAPALLI, PhD; JIACHEN ZHUO, MS; RICHARD N. PIERSON III, MD; BARTLEY P. GRIFFITH, MD; ROBERT S. POSTON. (2007): Heart Preservation Using Continuous Ex Vivo Perfusion Improves Viability and Functional Recovery. Circ J., 71; 153 –159.[P24]

LIU, Q., MONBALIU, D.,VEKEMANS, K.,PEETERS, R., KEYZER, F.DRESSELAERS, T.NI, Y., VAN HECKE, P., KOMUTA, M. BRASSIL, J.MARCHAL and G., PIRENNE, J. (2007): Can apparent diffusion coefficient discriminate ischemic from non-ischemic livers? A pilot experimental study. Transplantation Proc. 39(8); 2643-2646.[P23]

HOSGOOD, S.A., HARPER, S.J.F., KAY, M.D., ATUL BAGUL, REES, D. and NICHOLSON, M.L. (2007): Rate of Cooling In Organ Preservation. British Transplant Society 10th Ann. Congress Meeting. Abstr. No. P59. [P22]

MARK D. KAY, SARAH A. HOSGOOD, SIMON J. F. HARPER, ATUL BAGUL, HELEN L. WALLER, DOUGLAS REES AND MICHAEL L. NICHOLSON. (2006): Static normothermic preservation of porcine renal allografts using a novel non-phosphate buffered preservation solution. Transplant International. 20(1); 88 - 92.[P21]

KAY, M.D., HOSGOOD, S.A., HARPER, S.J.F., REES, D. and NICHOLSON, M.L. (2006a): STATIC NORMOTHERMIC PRESERVATION OF PORCINE RENAL ALLOGRAFTS USING A NOVEL NON-PHOSPHATE BUFFERED PRESERVATION SOLUTION. Association of Surgeons of Great Britain and Irelend Annual Scientific Meeting, Edinburgh. Abstr. 9704..[P34]

KAY, M.D., HOSGOOD, S.A., HARPER, S.J.F., REES, D. and NICHOLSON, M.L. (2006b): NORMOTHERMIC EX-VIVO FLUSH: A COMPARISON WITH STANDARD HYOTHERMIC METHODS IN PORCINE RENAL ALLOGRAFTS. Association of Surgeons of Great Britain and Irelend Annual Scientific Meeting, Edinburgh. Abstr. 9702. [P35]

HOSGOOD, S.A., HARPER, S.J.F., KAY, M.D., REES, D. and NICHOLSON, M.L. (2006): Optimal retrieval conditions in renal transplantation. A novel non-phosphate buffered preservation solution. British Transplant Society 8th Ann. Congress Meeting. Abstr. No. 10765. [P18]

KAY, M.D., HOSGOOD, S.A., HARPER, S.J.F., REES, D. and NICHOLSON, M.L. (2005): Static normothermic preservation of porcine renal allografts using a novel non-phosphate buffered preservation solution. British Transplant Society 8th Ann. Congress Meeting. Abstr. No. P131; RA5075. [P17]

KAY, M.D., HOSGOOD, S.A., HARPER, S.J.F., REES, D. and NICHOLSON, M.L. (2005): Normothermic versus hypothermic ex vivo flush. A comparison of a novel phosphate-free preservation solution and a standard hypothermic method in porcine renal allografts. British Transplant Society 8th Ann. Congress Meeting. Abstr. No. P132; RA5077. [P16]

REES, D. (1995): In vitro bioassay techniques - questionable validity using vertical bath technology and phosphate buffered solutions. Proceedings of the Physiological Society of New Zealand, 14;19 pp. [P33]

REES, D. and CLISSOLD L.C. (1995): Effect of Res-Del® RS-C solution on the viability of isolated rat heart preparations over 1-6 hours of cardioplegic arrest. Proceedings of the Physiological Society of New Zealand, 14; 19 pp.[P32]

REES D. and DALZIEL, J.E. (1994): Are pharmacological bioassay results valid when conducted in conventional phosphate buffered salines? Proceedings of the Anaesthesiology Group of New Zealand, May, 4 pp.

ANDREWS, J.R.H., AINSWORTH, R. and ABERNETHY, D (1994): Trichinella pseudospiralis in humans: description of a case and its treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene, 88; 200-203.

ROBINSON, B.J., LEE, E., REES, D., PURDIE, G.L. and GALLETLY, D.C. (1992): Betamethasone-induced resistance to neuromuscular blockade: A comparison of atracurium and vecuronium in vitro. ( Anesth. Analg. 74; 762-765).[P11]

PARR, S.M., ROBINSON, B.J., REES, D. and GALLETLY, D.C. (1991): An interaction between betamethasone and vecuronium. (Brit. J. Anaesthesia., 67;447-451).[P10]

REES, D. (1989a): Consideration of the inorganic and organic composition of mammalian perfusion solutions. In Isolated Perfused Organ Preparations. Eds.H.J. Döring & H.Dehnert. Biomesstechnik-Verlag March GmbH [ISBN 3-924638-57-8], 5; 85-94.[P9]

REES, D. (1989b): Isolated Perfused Kidney. In Isolated Perfused Organ Preparations. Eds. H.J. Döring & H. Dehnert. Biomesstechnik-Verlag March GmbH [ISBN 3-924638-57-8], 5; 123-132.

REES, D. (1988): The preservation of cellular function in isolated mammalian tissues/organ preparations (Proc. Physiol. Soc. N.Z. 8; 21 pp).[P7]

REES, D. (1986): The effect of the metabolic inhibitor, antimycin A3, on the pharmacological responsiveness of the rat detrusor muscle in vitro. (N.Z. J. Medicine, 99; 244 pp).[P6]

REES, D. (1985): The effect of phosphate buffered RS-I saline on the contractility of isolated rat heart preparations. (Proc. Physiol. Soc. N.Z. 5; 18 pp).[P5]

REES, D. (1983): The effect of aspartate, malate and D-fructose on the temperature dependent inotropic effect observed in vitro in mammalian skeletal muscle fibres. (Proc. 9th Cong. Int.Union of Physiol. Sci., 15; 155 pp).[P4]

REES, D. (1978b): Studies of immunoglobulin G in the aetiology of myasthenia gravis. (N.Z. J. Medicine, 88 (618); 165 pp).[P3]

REES, D. (1978a): A new non-phosphate based mammalian saline for long-term neurophysiological studies. (J. Physiol. 278; 8-9).[P2]

REES, D., BEHAN, P.O., BEHAN W.M.H. and SIMPSON, J.A. (1977): Attempts to passively transfer myasthenia gravis from humans to mice. 7th Symposium on Current Research into Muscular Dystrophy. (Birmingham, January 5-7, 16 pp).

AUDIT TRIAL REPORTS:

D. Bunton, E. Cooper and D. Smith; Biopta Ltd, Glasgow, UK. Biopta Technical Summary - Validation of Ex Vivo Human Atrial Trabeculae [Oct, 2008]

K. Newton, Ph.D. and D. Rees, Ph.D., Aqix Ltd, Imperial College London, UK. Summary Report: Assessment of a novel non-phosphate buffered solution, AQIX® RS-I, in the isolation and 24-hour culturing of human PBMC’s in comparison to RPMI medium. [Nov, 2008]

Pharmaceutical Client, USA and D. Rees, Ph.D., Aqix Ltd, Imperial College London, UK. Comparison of the histoculture viability of human colon biopsies stored and transported in AQIX® RS-I verses RPMI. [February, 2008]

Pharmaceutical Client, USA and D. Rees, Ph.D., Aqix Ltd, Imperial College London, UK. Comparison of the stability of RNA in histoculture sections of human colon biopsies stored and transported in AQIX® RS-I verses RPMI. [February, 2008]

F Jamali, S Darwiche, Z Otrock, N El-Kinge , M El-Sabban, Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon, and D.Rees, Aqix Ltd, Imperial College London, UK.

Phase I - Pilot ‘Safety’ Study: Assessment of a novel non-phosphate buffered solution, AQIX® RS-I, as a volume expander in a preclinical model of hypovolemic shock. [November, 2007]

Phase II - Assessment of a novel non-phosphate buffered solution, AQIX® RS-I, as a volume expander in a prclinical model of hypovolemic shock in comparison to LR Saline and Whole Autologous Blood. [March, 2008]

V.G. Wilson, S. Al-shalamani and S. Chinniah, School of Biomedical Sciences, University of Nottingham, England, UK. COMPARISON OF RESPONSIVENESS OF PORCINE ISOLATED CORONARY ARTERIES CULTURED IN KREBS-HENSELEIT SOLUTION AND AQIX® RS-I SOLUTION. [August, 2007]

M.Tarunina, B.Huhse & Y. Choo, Plasticell Ltd., Imperial College BioIncubator London, UK. Comparison of the effects on functionality and cell differentiation of Mouse ES-derived cardiomyocytes following incubation in conventional TC-media verses AQIX® RS-I solution. [July, 2007]

D. Bunton, E. Cooper and D. Smith; Biopta Ltd, Glasgow, UK. Ex Vivo Human Atrium Contractility Assays: Pharmacological Responsiveness to the Vasoreactive Drug, Milrinone (Primacor®). (June, 2007)

D. Bunton, E. Cooper, L. Rankin and D. Smith; Biopta Ltd, Glasgow, UK. Long-term Functional Viability of Human Bronchial biopsies preserved and perfused with AQIX® RS-I Solution. (December, 2007)

L.Dawson, Asterand (UK) Ltd, UK. [ASTERAND PRELIMINARY PROJECT REPORT 1.0] Assessment of AQIX® RS-I solution in functional pharmacology experiments using human isolated tissue. (March, 2007)

D. J. Chambers, Cardiac Surgical Research, The Rayne Institute, St Thomas’ Hospital, London, UK. Aqix® cardioplegia: a study to determine the efficacy of Aqix (RS-C) cardioplegia in comparison to that of St Thomas’ Hospital cardioplegia. [February, 2007]

M.D Kay, S.A Hosgood, S.J.F Harper, M.L. Nicholson; Renal Transplant Unit, Leicester General Hospital, England, UK.

Audit Trial Report I: Comparative study with conventional hypothermic preservation solutions. [January, 2005]

Audit Trial Report II:
(i)A comparison of a novel phosphate-free preservation solution and a standard hypothermic method in renal allografts. [January, 2005]
(ii)Static normothermic preservation of renal allografts using a novel non-phosphate buffered preservation solution. [January, 2005]

Audit Trial Report III: Assessment of a novel non-phosphate preservation solution, AQIX® RS-I, under hypothermic and normothermic static storage conditions. [May, 2005]

Audit Trial Report TR-1: The Investigation between AQIX® RS-I under hypothermic static storage conditions involving HTK, Soltran® in comparison to Machine Perfused KPS-1® solutions in long-term preservation using a porcine kidney model. [Feb, 2007]

W.C. Biddle, Life Technologies Inc., Buffalo, NY, USA. Summary Report: Evaluation of Res-Del® Solutions in embryonic stem (ES) cell culture for their potential in supporting cell attachment and growth, and as a holding media.

CRO – Reports

D. Rees, Animal Physiology Research Unit, Victoria University of Wellington, New Zealand. The effect of meclofenamate on the isolated rat uterus perifused with Res-Del® RS-I mammalian solution in a Res-Del® 589 perfusion bath. [ April,1992]

D. Rees and J.E. Dalziel, Animal Physiology Research Unit, Victoria University of Wellington, New Zealand. A critical appraisal on the pharmacology of Betamethasone. Research Report Bulletin; Organon-Technika Ltd,. Belgium, [May, 1994]

P.G.C. Douch and P.E. Morum, Ministry of Agriculture & Fisheries, Wallaceville, Wellington, NZ. Bioassay of Leukotrienes from Sheep intestine. [November, 1987]

AQIX TECHNOLOGY SOP DIRECTIVES

1.Instructions for the Storage, Transport & Perfusion of isolated tissues and organs in AQIX® RS-I fluid

2.DILUTION INSTRUCTIONS OF AQIX® RS-I [10x] CONCENTRATE SOLUTION FOR ISOLATED TISSUE OR ORGAN PERFUSION AND PRESERVATION

3.[SOP/ST/TR] - DRRSI0807 – The application of AQIX® RS-I solution in a Kit Method for Storage and Transport of Isolated Tissue Biopsy Samples

4.[SOP/ST/TR] - DRRSS0807 – The application of AQIX® RS-S solution in a Kit Method for Storage and Transport of Isolated Tissue Biopsy Samples